Racial differences in nasopharyngeal carcinoma in the United States-Reference-Cited by-同舟云学术

Racial differences in nasopharyngeal carcinoma in the United States

Published:2013-12 Issue:6 Volume:37 Page:793-802
ISSN:1877-7821
Container-title:Cancer Epidemiology
language:en
Short-container-title:Cancer Epidemiology

Author:

Wang Yu,Zhang Yawei,Ma Shuangge

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Epidemiology

Reference29 articles.

1. Initiative for Vaccine Research (IVR): Viral cancers,2012

2. American Cancer Society: how is nasopharyngeal cancer staged? http://www.cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-staging.

3. Demographic patterns for nasopharyngeal carcinoma in the United States;Levine;Int J Cancer,1980

4. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States;Burt;Int J Cancer,1992

5. Molecular pathology parameters in human nasopharyngeal carcinoma;Shi;Cancer,2002

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nasopharyngeal carcinoma in Sarawak : a 10-year review and update;European Archives of Oto-Rhino-Laryngology;2024-09-06

2. Nasopharyngeal cancer mortality in disaggregated Asian and non‐Asian Americans;Head & Neck;2024-07-18

3. Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area;World Journal of Surgical Oncology;2024-07-11

4. Enhancing Nasopharyngeal Carcinoma Survival Prediction: Integrating Pre- and Post-Treatment MRI Radiomics with Clinical Data;Journal of Imaging Informatics in Medicine;2024-04-30

5. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma;Journal of Medical Economics;2024-04